Arrowhead Pharmaceuticals reported early-stage human data for ARO-MAPT, an RNA interference medicine intended to lower tau in the central nervous system. The company said the highest dose reduced tau levels by an average of 73% after 105 days in healthy volunteers and described the regimen as potentially enabling once-every-three-month dosing, while stressing that safety and efficacy will require further study.